349 related articles for article (PubMed ID: 15695382)
21. Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families.
Maillet P; Chappuis PO; Khoshbeen-Boudal M; Sciretta V; Sappino AP;
Cancer Genet Cytogenet; 2006 Aug; 169(1):62-8. PubMed ID: 16875939
[TBL] [Abstract][Full Text] [Related]
22. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal.
Peixoto A; Santos C; Rocha P; Pinheiro M; Príncipe S; Pereira D; Rodrigues H; Castro F; Abreu J; Gusmão L; Amorim A; Teixeira MR
Breast Cancer Res Treat; 2009 Mar; 114(1):31-8. PubMed ID: 18363094
[TBL] [Abstract][Full Text] [Related]
23. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families.
Hansen Tv; Jønson L; Albrechtsen A; Andersen MK; Ejlertsen B; Nielsen FC
Breast Cancer Res Treat; 2009 May; 115(2):315-23. PubMed ID: 18546071
[TBL] [Abstract][Full Text] [Related]
24. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
[TBL] [Abstract][Full Text] [Related]
25. Phenotypic effects of heterozygosity for a BRCA2 mutation.
Warren M; Lord CJ; Masabanda J; Griffin D; Ashworth A
Hum Mol Genet; 2003 Oct; 12(20):2645-56. PubMed ID: 12928478
[TBL] [Abstract][Full Text] [Related]
26. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
Egeli U; Cecener G; Tunca B; Tasdelen I
Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
[TBL] [Abstract][Full Text] [Related]
27. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene.
McAllister KA; Bennett LM; Houle CD; Ward T; Malphurs J; Collins NK; Cachafeiro C; Haseman J; Goulding EH; Bunch D; Eddy EM; Davis BJ; Wiseman RW
Cancer Res; 2002 Feb; 62(4):990-4. PubMed ID: 11861370
[TBL] [Abstract][Full Text] [Related]
28. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs.
Vreeswijk MP; Kraan JN; van der Klift HM; Vink GR; Cornelisse CJ; Wijnen JT; Bakker E; van Asperen CJ; Devilee P
Hum Mutat; 2009 Jan; 30(1):107-14. PubMed ID: 18693280
[TBL] [Abstract][Full Text] [Related]
29. Pitfalls and caveats in BRCA sequencing.
Bellosillo B; Tusquets I
Ultrastruct Pathol; 2006; 30(3):229-35. PubMed ID: 16825125
[TBL] [Abstract][Full Text] [Related]
30. Molecular and in silico analysis of BRCA1 and BRCA2 variants.
Tommasi S; Pilato B; Pinto R; Monaco A; Bruno M; Campana M; Digennaro M; Schittulli F; Lacalamita R; Paradiso A
Mutat Res; 2008 Sep; 644(1-2):64-70. PubMed ID: 18694767
[TBL] [Abstract][Full Text] [Related]
31. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of cancer cell growth by BRCA2.
Wang SC; Shao R; Pao AY; Zhang S; Hung MC; Su LK
Cancer Res; 2002 Mar; 62(5):1311-4. PubMed ID: 11888897
[TBL] [Abstract][Full Text] [Related]
33. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
[TBL] [Abstract][Full Text] [Related]
34. Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
Chen X; Truong TT; Weaver J; Bove BA; Cattie K; Armstrong BA; Daly MB; Godwin AK
Hum Mutat; 2006 May; 27(5):427-35. PubMed ID: 16619214
[TBL] [Abstract][Full Text] [Related]
35. Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.
Pejovic T; Yates JE; Liu HY; Hays LE; Akkari Y; Torimaru Y; Keeble W; Rathbun RK; Rodgers WH; Bale AE; Ameziane N; Zwaan CM; Errami A; Thuillier P; Cappuccini F; Olson SB; Cain JM; Bagby GC
Cancer Res; 2006 Sep; 66(18):9017-25. PubMed ID: 16982743
[TBL] [Abstract][Full Text] [Related]
36. CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12.
Maguire P; Holmberg K; Kost-Alimova M; Imreh S; Skoog L; Lindblom A
Int J Mol Med; 2005 Jul; 16(1):135-41. PubMed ID: 15942690
[TBL] [Abstract][Full Text] [Related]
37. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
[TBL] [Abstract][Full Text] [Related]
38. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
[TBL] [Abstract][Full Text] [Related]
39. Lower level of BRCA2 protein in heterozygous mutation carriers is correlated with an increase in DNA double strand breaks and an impaired DSB repair.
Arnold K; Kim MK; Frerk K; Edler L; Savelyeva L; Schmezer P; Wiedemeyer R
Cancer Lett; 2006 Nov; 243(1):90-100. PubMed ID: 16448746
[TBL] [Abstract][Full Text] [Related]
40. A recombination-based method to characterize human BRCA1 missense variants.
Guidugli L; Rugani C; Lombardi G; Aretini P; Galli A; Caligo MA
Breast Cancer Res Treat; 2011 Jan; 125(1):265-72. PubMed ID: 20737206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
